Chile surrogacy: medical and donor requirements
The short answer: separate law, clinical practice and funding
Anyone considering a surrogacy arrangement in Chile needs to distinguish four questions: what Chilean law expressly requires, what clinical guidance recommends, what a particular clinic requires, and what a funding programme will pay for. They are not interchangeable. A clinic’s checklist may be medically prudent without being a statutory rule; a funding exclusion does not, by itself, make a procedure unlawful.
Chile has no comprehensive surrogacy statute or universal donor-screening schedule. They do identify narrower ministerial instruments for IVF/embryo transfer and low-complexity infertility; their current scope and enforceability need confirmation. General patient-rights, genetic-safeguard and health-service rules still matter.
The legal landscape and current legislative proposals
A 2023 report from Chile’s Library of Congress says surrogacy is not specifically regulated and that Civil Code art. 182 addresses parentage after ART, not the surrogacy procedure itself. The report is research, not legislation. No later comprehensive surrogacy or donor-screening law was identified in the official sources.
The issue is active in Congress. The Senate Women and Gender Equity Committee approved bill 18546-34 on altruistic surrogacy in general on 7 September 2026. Bill 17922-11 on embryo transfer to a gestational carrier remained pending after Senate Health Committee discussion on 11 August 2026. As of 24 October 2026, the Chamber’s official tracker classifies bill 17337-07, which proposes a ban and sanctions, as being in the first constitutional stage; its history records a committee report dated 24 July 2026. These are proposals, not enacted rules.
Do not describe a bill as a current medical requirement, prohibition or licence condition. Recheck each bill immediately before relying on this article.
Civil Code articles 182 and 183: consent is not a parentage solution
Article 182 of the Chilean Civil Code determines filiation for a child born through assisted reproductive techniques in relation to the two people who underwent them; that filiation cannot be challenged or replaced. Article 183 generally determines maternity by childbirth when the birth and identities are recorded in the civil registry.
Neither provision creates a complete surrogacy procedure. The meaning of “the two persons who underwent” ART and its interaction with birth-based maternity under article 183 require case-specific analysis. Do not infer parentage from genetics, an embryo-transfer form, a clinic statement or intended-parent consent alone.
Before creating or transferring an embryo, obtain Chilean legal advice on the exact arrangement: who provides each gamete, who carries the pregnancy, which consents will be signed, and how parentage and birth registration may be addressed. A medical protocol or private agreement does not resolve those legal questions.
Patient consent, information and medical records
Law No. 20.584 generally governs rights and duties in health care. Article 14 protects the right to accept or refuse treatment freely, voluntarily, expressly and on an informed basis. The professional must provide adequate, sufficient and understandable information. Written records are required for surgery, invasive procedures and procedures involving a known relevant health risk; the information and acceptance or refusal must be recorded in the clinical file.
These rules apply to each person receiving care. Intended parents’ signatures do not replace the carrier’s or donor’s consent to procedures performed on them. Request separate, stage-specific forms explaining treatment, foreseeable risks, alternatives, reproductive-material storage or use, and consent limits for future use. Confirm forms and withdrawal rules with the clinic and counsel.
Law No. 20.584 also requires providers to retain clinical files for at least 15 years and protect their confidentiality. Information in clinical files and treatment records is sensitive data. Request copies of consents, test reports and treatment records through the clinic’s documented process, and clarify who may access donor-identifying and genetic information.
Genetic safeguards: what Law No. 20.120 does and does not say
Law No. 20.120 concerns human scientific research and the human genome and prohibits human cloning. It prohibits eugenic practices except genetic counselling, bars arbitrary genetic discrimination and protects genetic information. It also contains consent safeguards for research on genetic identity. These rules do not mean every genetic test or donor-selection practice is prohibited.
The law does not provide a complete, generally applicable list of required donor infectious-disease tests, genetic panels, age limits or family-history criteria for surrogacy. Whether a proposed genetic test, embryo-selection decision or use of genetic data engages a particular provision depends on its purpose and circumstances. Ask the treating specialist to explain the clinical rationale and ask Chilean counsel to review any unusual genetic-selection or research component.
What Ministry guidance and older IVF instruments say
The Ministry of Health’s 2015 Guide for the Study and Treatment of Infertility is official clinical guidance directed at infertility care. It describes clinical assessment and assisted-reproduction pathways, including semen analysis, reproductive evaluation and serology. For the pre-assessment described for artificial insemination, it lists serology for both partners for RPR, HIV, hepatitis B and hepatitis C. It also states that treatment should be indicated and monitored by appropriately trained specialists and that procedures should be performed with informed consent.
These passages describe possible clinical testing; they do not establish a binding donor-screening rule for every clinic, gamete type or surrogacy arrangement. The 2015 guide concerns infertility treatment, not a complete surrogacy programme, and is not a dedicated statute. Ask for the current clinic protocol and the legal or clinical source for each test, exclusion and retesting interval.
The BCN report also identifies MINSAL Exenta Resolution 1072 of 28 June 1985, titled “Normas Aplicables a la Fertilización in Vitro y la Transferencia Embrionaria,” and Technical General Standard No. 159 of 2013 on low-complexity infertility. Article 8 of the 1985 directive describes reporting and record duties for IVF/embryo-transfer programmes and states that all normal fertilised ova should be transferred, with no embryo freezing for delayed transfer or research. Do not present the cryopreservation wording as a universally enforced current rule without Chilean legal confirmation. Ask the clinic and counsel which instrument applies to the proposed procedure.
FONASA rules: an eligibility and funding issue, not a general ban
Resolution Exenta No. 277, in the version available through the official Chilean legal database as last amended on 26 April 2024, sets technical-administrative rules for FONASA’s health-benefit tariff arrangements. Its high-complexity assisted-fertilisation package contains programme-specific clinical eligibility and documentation conditions. These include medical evaluation, ovarian-reserve assessment and exclusion from that funded treatment where a person in the couple has an active sexually transmitted infection, particularly chlamydia or gonorrhoea, or HIV with a detectable viral load.
The same package expressly excludes financing for sperm-bank donors, egg donation and a surrogate uterus. That statement concerns what the specified FONASA package funds. It must not be rewritten as a nationwide criminal prohibition or as proof that all privately funded ART or all surrogacy-related medical care is forbidden. Conversely, do not promise FONASA coverage for donor material or a gestational carrier on the basis of general IVF coverage.
If public funding is relevant, obtain written confirmation of the applicable resolution, eligibility route, referral, tests and excluded costs. The reviewed version was last amended in April 2024; check for later changes before committing funds.
Donor screening: do not turn clinic practice into a legal rule
The reviewed official materials do not establish a single statutory checklist for every sperm, egg or embryo donor or gestational carrier, nor universal rules on donor age, genetic panels, quarantine, repeat testing or anonymity. This does not mean that no other sanitary rule, current protocol or professional standard applies.
A clinic may screen infectious, genetic, reproductive and psychosocial risks in detail. Such requirements may be sensible conditions of its service, but the clinic should label them accurately as law, administrative rule, official guidance, professional recommendation or internal policy. If a test is said to be “required by Chilean law,” ask for the provision or official document.
Equally, the absence of a located universal schedule does not mean screening is unnecessary. Ask the specialist to identify which tests are clinically indicated for the donor, the carrier and any intended parent providing gametes; how results are reviewed; what happens after a positive or inconclusive result; and how samples, records and identities are traced and protected.
A practical matrix for checking each requirement
Use the following matrix in the first clinic meeting. It is designed to identify the source of each requirement, not to replace the clinician’s judgment or to certify that a programme is legally permissible.
| Issue to verify | What the evidence means | What to request |
|---|---|---|
| Consent and risk information | General patient-rights law applies; written consent is required for invasive or materially risky procedures. | Current consent form for each person, information sheet, alternatives and risks. |
| Infection testing | The 2015 infertility guide lists selected tests in an artificial-insemination work-up; this is not a universal donor statute. | Current donor/carrier protocol, exact panel, timing, retesting and response to results. |
| Genetic testing and family history | Law No. 20.120 contains genetic safeguards but no complete donor panel. | Clinical rationale, scope of tests, data-use permissions and legal review if selection is unusual. |
| FONASA eligibility and payment | The specified high-complexity package has its own conditions and excludes donor-bank sperm, egg donation and surrogate-uterus financing. | Written confirmation of coverage, exclusions, self-pay costs and the version of the applicable rule. |
| 1985 IVF/embryo-transfer directive | Resolution 1072 art. 8 describes reporting/record duties and says no embryo freezing for delayed transfer or research; current scope and enforceability require confirmation. | Copy of the directive and written confirmation of its application to this clinic, procedure and embryo storage. |
Questions to put to the clinic before treatment
Ask the clinic to answer in writing so medical necessity, internal criteria and legal restrictions can be distinguished.
- Which legal provisions, administrative rules, official guidelines and internal policies govern the proposed procedure? Please identify the title, date and version of each document.
- Who is screened: the gestational carrier, each intended parent, each sperm or egg donor, and any person whose gametes are used? Which tests apply to each person, and why?
- What are the test methods, validity periods, retesting triggers, acceptance thresholds and procedures for a positive, inconclusive or outdated result? Which are clinical decisions rather than statutory thresholds?
- How are medical history, family history, genetic results and infectious-disease results handled? Who can see them, how are they stored, and what information can be disclosed to the future child or other participants?
- Who gives consent for stimulation, retrieval, fertilisation, embryo testing, storage and transfer? Are there separate forms for each stage and each participant? What choices remain open after signing?
- Does the clinic actually offer treatment involving a gestational carrier, and what current health authorisation and professional credentials cover the services it will perform? Do not confuse general facility authorisation with a special surrogacy licence.
Documents to obtain and preserve
Before treatment, create a file documenting the clinical pathway and legal assumptions. Obtain the current protocol, relevant facility authorisations and professional registrations, treatment plan, itemised estimate, any funding confirmation and each person’s stage-specific consent form.
Keep histories and assessments for the carrier, intended parents and donors; lab and imaging reports; donor-screening results or a record of what will be disclosed; genetic-counselling notes where applicable; embryo creation, testing, storage and transfer records; and signed decisions on use or disposal of reproductive material. Ask how records are corrected and copies transferred securely.
Do not collect or circulate another participant’s sensitive medical or genetic data without a proper basis and the clinic’s secure process. Keep the original signed documents and the dated versions of policies that were in force when each consent was given.
Warning signs and what to do if an answer is unclear
Pause before stimulation, retrieval, fertilisation or embryo transfer if the clinic cannot identify the source of a claimed legal duty, gives only verbal assurances, cannot explain consent or treats intended parents’ wishes as overriding the carrier’s medical decisions. A clinical recommendation may be reasonable, but it is not law without an identified legal basis.
If FONASA rejects coverage, request the written decision, tariff provision and review route. If screening or consent appears inconsistent, request a written explanation from the clinic. Complaint and court options depend on the decision, provider and facts.
For parentage or enforceability questions, obtain separate Chilean family-law advice before the embryo-transfer stage. A dispute over parentage is not resolved simply by repeating a donor test, changing a consent form or relying on an intended-parent agreement.
Decision rule: proceed only after the gaps are named
Do not search for a mythical universal donor-test list. Obtain the current clinic protocol, identify the source of each requirement, confirm consent and records, check funding separately and get case-specific advice on arts. 182–183 before an irreversible clinical step.
The law and legislative proposals must be rechecked at the decision date, the clinical protocol must be reviewed by a Chilean reproductive-medicine specialist, and the parentage analysis requires Chilean legal review.
Official sources and materials
- [S01] Código Civil de Chile (arts. 182–183), Biblioteca del Congreso Nacional
- [S02] Ley N.º 20.584, derechos y deberes de las personas en la atención de salud (version identified as of 16 February 2026)
- [S03] Ley N.º 20.120, investigación científica en el ser humano y genoma humano
- [S04] Guía para el estudio y tratamiento de la infertilidad, Ministerio de Salud de Chile (2015)
- [S05] Resolución Exenta N.º 277, reglas técnico-administrativas FONASA (last listed amendment: 26 April 2024)
- [S06] Biblioteca del Congreso Nacional, Gestación por sustitución: Chile y legislación extranjera (abril de 2023)
- [S07] Senado de Chile, Comisión de Mujer y Equidad de Género, 7 septiembre 2026, Boletín 18546-34
- [S08] Senado de Chile, Comisión de Salud, 11 agosto 2026, Boletín 17922-11
- [S09] Cámara de Diputadas y Diputados, Boletín 17337-07
- [S10] Ministerio de Salud de Chile, Resolución Exenta N.º 1072 (28-06-1985), FIV y transferencia embrionaria; link cited by BCN; direct access unavailable
- [S11] Corte Interamericana de Derechos Humanos, Artavia Murillo y otros vs. Costa Rica; reproduces Article 8 of Chilean Exenta Resolution 1072/1985
- [S12] Ministerio de Salud de Chile, Norma General Técnica N.º 159 (2013), infertilidad de baja complejidad; link cited by BCN; direct access unavailable
